One of the most discussed uses of PGT from an ethical point of view is hereditary breast and ovarian cancer syndrome (HBOC) in which the risk is induced by carrying BRCA1/2 mutations which increase the risk for breast and ovarian cancer but not before 30 years of age and usually much later. This evidence concerns the gene BRCA1 and hereditary breast ovarian cancer syndrome.